Pf Prism Cv Company Profile

✉ Email this page to a colleague

PF PRISM CV has sixteen approved drugs.

There are twenty-nine US patents protecting PF PRISM CV drugs.

There are six hundred and twelve patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011		RX	Yes	No	8,217,057	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Pf Prism Cv	VFEND	voriconazole	INJECTABLE;INTRAVENOUS	021267-001	May 24, 2002	AP	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	CAPSULE;ORAL	217729-001	Sep 26, 2023		RX	Yes	No	11,103,497*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-001	Sep 4, 2012		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002	5,212,155*PED	⤷ Try a Trial
Pf Prism Cv	RAPAMUNE	sirolimus	SOLUTION;ORAL	021083-001	Sep 15, 1999	5,100,899*PED	⤷ Try a Trial
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	8,455,539*PED	⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-003	Oct 27, 2017	6,002,008	⤷ Try a Trial
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	RE40183	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	1 mg and 2 mg	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-release Tablets	50 mg and 100 mg	➤ Subscribe	2012-02-29
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100mg and 500mg	➤ Subscribe	2016-09-06
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2008-09-12
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2010-10-08
➤ Subscribe	Injection	25 mg/mL, 1.8 mL vial	➤ Subscribe	2011-05-25
➤ Subscribe	Tablets	0.5 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Extended-release Tablets	25 mg	➤ Subscribe	2015-05-08
➤ Subscribe	Tablets	1 mg and 5 mg	➤ Subscribe	2018-02-23
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	50 mg and 200 mg	➤ Subscribe	2008-04-14
➤ Subscribe	For Injection	50 mg per vial	➤ Subscribe	2009-06-15

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1786785	12/2013	Austria	⤷ Try a Trial	PRODUCT NAME: CRIZOTINIB, BEVORZUGT IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, HYDRATS ODER SOLVATS; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
1666481	CA 2017 00035	Denmark	⤷ Try a Trial	PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324
1666481	132017000095300	Italy	⤷ Try a Trial	PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324
1786785	C300587	Netherlands	⤷ Try a Trial	PRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023
1666481	PA2017025	Lithuania	⤷ Try a Trial	PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.